Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity

Cancer Letters

Volumn 120, Issue 2, 1997, Pages 165-171

  Hyder, Salman M ^a   Chiappetta, Constance ^a   Stancel, George M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antiestrogens; Estrogen receptor; Vascular endothelial growth factor

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; CLOMIFENE; MESSENGER RNA; NAFOXIDINE; PARTIAL AGONIST; TAMOXIFEN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE INDUCTION; NEWBORN; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS; UTERUS BLEEDING; UTERUS DISEASE;

ANIMALS; BLOTTING, NORTHERN; CLOMIPHENE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; LYMPHOKINES; NAFOXIDINE; OVARIECTOMY; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STILBENES; TAMOXIFEN; TIME FACTORS; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA;

EID: 0030660110     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00306-6     Document Type: Article

References (32)

1. Early Breast Cancer Trialists Collaborative Group Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet. 339:1992;1-15.
2. Lerner L.J., Jordan V.C. Development of antiestrogens and their use in breast cancer: 8th Cain Memorial Award Lecture. Cancer Res. 50:1990;4177-4189.
3. Henderson B.E., Ross R.K., Pike M.C. Hormonal chemoprevention of cancer in women. Science. 259:1992;633-638.
4. Jordan V.C. Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res. Treat. 15:1990;125-136.
5. Chlebowski R.T., Butler J., Nelson A., Lillington L. Breast cancer chemoprevention. Cancer. 72:1993;1032-1037.
6. Jordan V.C. An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Ann. N.Y. Acad. Sci. 768:1995;141-147.
7. Cohen I., Altaras M.M., Beyth Y. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet. Gynecol. 83:1994;158.
8. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. NSABP Contributors, Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:1994;527-537.
9. Ismail S.M. Pathology of endometrium treated with tamoxifen. J. Clin. Pathol. 47:1994;827-833.
10. Bissett D., Harnett A.N., Canney P.A., McMurray A., Leake R., George W.D., Paul J., Kaye S.B. Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer - a feasibility study. Breast. 5:1997;92-95.
11. Wakeling A.E. Tissue-specific actions of antioestrogens. Mutat. Res. Fundam. Mol. Mech. 333:1995;45-49.
12. Katzenellenbogen B.S., Montano M.M., Ekena K., Herman M.E., McInerney E.M. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res. Treat. 44:1997;23-38.
13. Parker M.G. Structure and function of estrogen receptor. Vit. Horm. 51:1995;267-287.
14. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B., Pike J.W., McDonnell D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8:1994;21-30.
15. Colletta A.A., Benson J.R., Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res. Treat. 31:1994;5-9.
16. Cabot M.C., Zhang Z.C., Giuliano A.E. Tamoxifen elicits rapid transmembrane lipid signal responses in human breast cancer cells. Breast Cancer Res. Treat. 36:1995;299-306.
17. Gundimeda U., Chen Z.H., Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J. Biol. Chem. 271:1996;13504-13514.
18. Hyder S.M., Stancel G.M., Chiappetta C., Murthy L., Boettgertong H.L., Makela S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res. 56:1996;3954-3960.
19. Gagliardi A., Collins D.C. Inhibition of angiogenesis by antiestrogens. Cancer Res. 53:1993;533-535.
20. Gagliardi A.R., Hennig B., Collins D.C. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic-growth factors. Anticancer Res. 16:1996;1101-1106.
21. Loose-Mitchell D.S., Chiappetta C., Stancel G.M. Estrogen regulation of c-fos messenger ribonucleic acid. Mol. Endocrinol. 2:1988;946-951.
22. Weisz A., Bresciani F. Estrogen induces expression of c-fos and c-myc in rat uterus. Mol. Endocrinol. 2:1988;816-824.
23. Nephew K.P., Polek T.C., Akcali K.C., Khan S.A. The antiestrogen tamoxifen induces c-fos and jun-B, but not c-jun or jun-D protooncogenes in the rat uterus. Endocrinology. 133:1993;419-422.
24. Kirkland J.L., Murthy L., Stancel G.M. Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent uterus. Mol. Pharmacol. 43:1993;709-714.
25. Gradishar W.J., Jordan V.C. The clinical potential of new antiestrogens. J. Clin. Oncol. 15:1997;480-489.
26. Cullinan-Bove K., Koos R.D. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology. 133:1993;829-837.
27. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 36:1995;127-137.
28. Katzenellenbogen B.S. Estrogen and antiestrogen action studies in reproductive target studies and tumors. Adv. Exp. Med. Biol. 117:1979;111-132.
29. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
30. Gasparini G., Fox S.B., Verderio P., Bonoldi E., Bevilacqua P., Boracchi P., Dante S., Marubini E., Harris A.L. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin. Cancer Res. 2:1996;1191-1198.
31. Rochefort H., Garcia M., Borgna J.-L. Absence of correlation between antiestrogen activity and binding affinity for the estrogen receptor. Biochem. Biophys. Res. Commun. 88:1979;351-357.
32. S.M. Hyder, C. Chiappetta, L. Murthy, G.M. Stancel, Selective inhibition of estrogen regulated gene expression by pure antiestrogen ICI 182,780. Cancer Res. 1997, in press.